Osimertinib Will Be New Standard for Some NSCLCs

Abstract: In the international phase III LAURA trial, patients with inoperable EGFR-stage III non–small cell lung cancer that doesn’t worsen during or soon after chemoradiotherapy derived a significant progression-free survival (PFS) benefit with the EGFR-directed therapy osimertinib compared with a placebo. Median PFS was 39.1 months and 5.6 months, respectively, and median duration of response was 36.9 months and 6.5 months, respectively.